Is there a risk of brain bleeding with tenecteplase for a minor ischemic stroke?

Tenecteplase is a clot-busting drug given through a vein to some people with minor ischemic stroke, which is a stroke caused by a blocked blood vessel that produces mild symptoms. Because the drug works by dissolving clots, it can also cause bleeding, including bleeding inside the brain. This is called intracranial hemorrhage, and it is the main safety concern doctors weigh when deciding whether to use it.

The short answer: bleeding in the brain is a recognized risk of tenecteplase, but in the largest trial of minor stroke it was not clearly more common with the drug than with standard care ⁹¹⁰. A small report describes three fatal brainstem bleeds after tenecteplase in minor stroke patients who had poorly controlled high blood pressure ¹¹. So the risk is real but appears uncommon, and certain patients may be at higher risk.

What the research says

The best evidence on this question comes from the TEMPO-2 trial, which compared tenecteplase with standard care in people with minor stroke (a National Institutes of Health Stroke Scale score of 5 or less) who had a blocked vessel or reduced blood flow seen on imaging within 12 hours of symptoms ¹⁰. A post hoc analysis of that trial looked at safety and outcomes in patients older than 80 versus those 80 and younger, and it tracked adverse events including bleeding ⁹. In the recanalization analysis of TEMPO-2, safety outcomes specifically included bleeding events, stroke progression, and death ¹⁰. Together these analyses provide the main picture of how often bleeding occurs with tenecteplase in minor stroke ⁹¹⁰.

It is worth noting that the TEMPO-2 analyses focus on functional recovery and vessel reopening as their main outcomes, and report bleeding as a safety measure rather than as the central question ⁹¹⁰. That means the trial gives useful but not exhaustive information about bleeding risk specifically.

A separate report describes three patients with minor ischemic stroke who developed bleeding in the brainstem right after receiving tenecteplase, and all three died ¹¹. All three had high blood pressure on arrival, and even though their blood pressure was lowered to guideline-recommended levels before treatment, the bleeds still happened ¹¹. The authors suggest that people with a history of poorly controlled high blood pressure may need especially careful risk assessment and blood pressure management if thrombolysis is considered ¹¹. This is a small case series, so it cannot tell us how common this problem is, only that it can occur ¹¹.

For context, bleeding in the brain is a known complication of clot-busting treatment in stroke more broadly. In a review of patients with heart failure who had mechanical clot removal for ischemic stroke, the rate of symptomatic intracranial hemorrhage was not significantly different between those with and without heart failure ⁷. That finding is about a different treatment and population, but it shows that bleeding risk is a standard safety concern tracked across stroke studies ⁷.

What to ask your doctor

• What is my personal risk of bleeding in the brain if I receive tenecteplase for a minor stroke, based on my blood pressure and other health conditions?
• How is my blood pressure being managed before and during treatment, and does my history of blood pressure control change the plan?
• What signs of bleeding should I or my family watch for after treatment, and when should we seek help?
• How do the benefits of tenecteplase compare with the risks for someone with my specific stroke features?
• Are there alternative treatment options if my bleeding risk seems too high?